Subcutaneous immunotherapy for cancer can cause many of the same side effects as intravenous (IV) immunotherapy because it involves the same medications. Injection site reactions are a common but ...

A Prescription Drug User Fee Act target date of May 24, 2026 has been set for the application. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble ...

2. It may reduce reliance on high-dose opioids/benzodiazepines and, in some cases, postpone the need for palliative sedation therapy This retrospective single-centre chart review from a New Zealand ...

A subcutaneous formulation of anifrolumab would allow patients the ability to self-administer the medication outside of a hospital or clinic setting. Full results were announced from a phase 3 trial ...

You may want to lose body fat but might not know exactly where fat is stored in your body. That’s when knowing the difference between subcutaneous fat and visceral fat can be handy. The main ...

aDepartment of Medicine ‘B’, Sheba Medical Center, Ramat Gan, Israel Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been increasingly ...

This discussion compares subcutaneous and intravenous immunotherapy delivery, highlighting differences in clinical use, patient convenience, and overall treatment experience. This program examines the ...

Dose intensification of subcutaneous vedolizumab is beneficial for patients with IBD, particularly those with UC. Subcutaneous vedolizumab dose escalation is associated with clinical improvement in ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.